Publications
Partners
Cape Town - South Africa has awarded Cipla Medpro a R345m ($32.6m) share in the national respiratory tender as Africa's most advanced economy seeks to cut high asthma mortality rates, the company said on Thursday.
"In South Africa, asthma is the third most common cause of hospital admissions of children, yet only 2% of asthmatics receive treatment," chief executive Paul Miller said in a statement.
South Africa has the world's fourth highest asthma death rate among 5- to 35-year olds, with thousands dying each year from a disease which causes shortness of breath, wheezing and coughing, according to the Global Initiative for Asthma.
The contract runs from the beginning of next month to April 30, 2017 and will see South Africa's third largest pharmaceutical company providing asthma medication.
"In South Africa, asthma is the third most common cause of hospital admissions of children, yet only 2% of asthmatics receive treatment," chief executive Paul Miller said in a statement.
South Africa has the world's fourth highest asthma death rate among 5- to 35-year olds, with thousands dying each year from a disease which causes shortness of breath, wheezing and coughing, according to the Global Initiative for Asthma.
The contract runs from the beginning of next month to April 30, 2017 and will see South Africa's third largest pharmaceutical company providing asthma medication.
